MASON, Ohio--(BUSINESS WIRE)--May 2, 2016--
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for
atrial fibrillation (Afib) and left atrial appendage management, today
announced that it will present at the UBS Global Healthcare Conference
at the Grand Hyatt in New York on Monday, May 23, 2016. Management is
scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of
the presentation may be accessed by visiting the Investors page of
AtriCure’s corporate website at www.atricure.com.
A replay of the presentation will be available for 90 days following the
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy™ Ablation System is the first and only surgical device approved
for the treatment of persistent and longstanding persistent forms of
Afib in patients undergoing certain open concomitant procedures.
AtriCure’s AtriClip left atrial appendage management (LAAM) exclusion
device is the most widely sold device worldwide that is indicated for
the occlusion of the left atrial appendage. The company believes
cardiothoracic surgeons are adopting its ablation and LAAM devices for
the treatment of Afib and reduction of Afib related complications such
as stroke. AtriCure recently acquired nContact, a leader in minimally
invasive technology for epicardial ablation. nContact’s mission is to
transform the underserved arrhythmia population through a
multidisciplinary epicardial-endocardial ablation approach. Afib affects
more than 33 million people worldwide.For more information
or follow us on Twitter @AtriCure.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160502006040/en/
Source: AtriCure, Inc.
Senior Vice President and
Chief Financial Officer